The Slovenian-based (Novo Mesto) international generic pharmaceutical company Krka saw its “group net profit increase 41% in 2017 to EUR 152.6m, on sales that rose 8% to EUR 1.27bn, a new record for the company, show unaudited results released on Thursday”, the STA reports.
Prescription drugs are still the business’s “ace” as it contributes nearly 83% to the overall sales.
Regionally wise, Eastern Europe remains the leader as it accounts for almost a third of overall sales, grew at a rate of 17%, Central Europe by 6% whereas Western Europe’s revenue “was almost flat, mostly due to a 13% decline in Germany.”
Posted sales reached EUR 1.2bn, translating into a nearly 12% rise. Net profit rose almost 50% to EUR 153.7m…. / IBNA